Clinical RoundupFree UNC researchers examine approaches to deliver radiation to tumors while sparing healthy tissue May 07, 2021Vol.47 No.18
Clinical RoundupFree City of Hope opens phase II clinical trial to test if intake of mushroom-powder tablets could slow the progression of prostate cancer May 07, 2021Vol.47 No.18
Drugs & TargetsFree Keytruda receives FDA Accelerated Approval for HER2-positive gastric cancer May 07, 2021Vol.47 No.18
Drugs & TargetsFree Tibsovo sNDA receives FDA acceptance and Priority Review for IDH1-mutated cholangiocarcinoma May 07, 2021Vol.47 No.18
Drugs & TargetsFree Opdivo sBLA receives FDA acceptance and Priority Review for adjuvant treatment for patients with muscle-invasive urothelial carcinoma May 07, 2021Vol.47 No.18
Drugs & TargetsFree Xtandi approved by European Commission for men with metastatic hormone-sensitive prostate cancer May 07, 2021Vol.47 No.18
Drugs & TargetsFree Janssen submits Marketing Authorization Application to EMA seeking approval of cilta-cel for relapsed and/or refractory multiple myeloma May 07, 2021Vol.47 No.18
Conversation with The Cancer LetterFree We ask FDA to explain “dangling” accelerated approvals—and this week’s ODAC agenda April 30, 2021Vol.47 No.17By Paul Goldberg
FreeIn the Archives Roswell Park’s Eva Noles and NCI’s Carl Baker: “When I start something, I want to finish it” April 30, 2021Vol.47 No.17
